ASMB (31) AVTX (34) RZLT (33) CAPR (49) ⌘ Pro Terminal →

Altimmune Inc. (ALT) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell ALT stock right now?

Altimmune Inc. (ALT) currently earns a Roarable Rating of D- (Sell — SELL) with 38/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is ALT's 12-month price target and RQD AI Jury consensus?

ALT's 12-month base price target is $1.95 (range $1.52 to $6.76), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$2.14 +1.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.14

Altimmune Inc. (ALT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $416.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.14 (+0.15%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALT)Realized 20D OHLCV Swing Band: ±10.6%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY ALT SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (34% of score)

20D Institutional Volume Accumulation (±10.6% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (32% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 26.7 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.61-15.7% Next Q

Q2 (-2Q)

Grade D$2.20-3.6% Next Q

Q3 (-1Q)

Grade D$2.12+0.9% Next Q

Current

Grade D-$2.14-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.83) and Max Pain ($2.25) forces dealer call-delta covering toward $6.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

26.730 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

1.30>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $2$2.14H: $6

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ALT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-34.7% ROIC with 42.0% gross margin and -16.23% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 1.30 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

16/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like ALT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALT)

✓Walkthrough of ALT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.69%▼ SUPPORT BREAKDOWN

2026-10-30O $2.13H $2.14L $1.99C $2.14VOL 3.52M

RES: $3.68SUP: $2.80SMA50: $2.83SMA200: $3.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALT Butterfly Map → + Track ALT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +105.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALT)

Health Care Rank #709 of 1016 ⚔️ ASMB vs ALT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALT vs. ASMB, AVTX, RZLT, CAPR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Altimmune Inc. (ALT) ranks #709 by composite RQD confidence (38/100, grade D-) and #476 by equity capitalization ($416.3M). Within this direct 5-issuer industry benchmark cohort, ALT leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. CAPR currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ALT at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALT ACTIVE Altimmune Inc.	D-	38/100	—	—	-34.7%	+1.91%	$416.3M	Benchmark Subject
ASMB Assembly Biosciences Inc.	E	31/100	—	—	-6.5%	+1.41%	$424.7M	/asmb-vs-alt →
AVTX Avalo Therapeutics Inc.	E	34/100	—	—	-35.0%	+4.49%	$399.0M	/avtx-vs-alt →
RZLT Rezolute Inc. (NV)	E	33/100	—	—	-35.0%	-2.37%	$398.5M	/rzlt-vs-alt →
CAPR Capricor Therapeutics Inc.	D	49/100	—	—	-35.0%	+6.42%	$385.5M	/capr-vs-alt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001326190

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Altimmune Inc. (ALT) reported GAAP revenue of $41.0K (+105.0% vs. FY2024 revenue of $20.0K , and -90.4% cumulative change since FY2023) , GAAP net income of -$88.1M, operating cash flow of -$67.5M, and free cash flow of -$67.5M (+15.4% YoY). On the balance sheet, ALT closed FY2025 with $279.9M in total assets against $34.3M in total debt (Altman Z-Score: 1.30, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$41.0K	-$88.1M	-$67.5M	-$67.5M	$279.9M	$34.3M
FY2024 (FY)	2024-12-31	$20.0K	-$95.1M	-$79.8M	-$79.8M	$139.3M	—
FY2023 (FY)	2023-12-31	$426.0K	-$88.4M	-$75.8M	-$75.8M	—	—

3. ALT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Altimmune Inc. (NASDAQ: ALT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.14 (+1.91% 1D, market cap $416.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALT ranks #709 in composite RQD confidence.

How does ALT compare to ASMB and AVTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, ASMB (Assembly Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -6.5%, cap $424.7M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M). Among the 5-stock peer group, ALT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALT?

Per ALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326190), Altimmune Inc. generated $41.0K in revenue (+105.0% YoY), -$88.1M in net income, and -$67.5M in free cash flow against $279.9M in total assets and $34.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALT trading relative to its 50-day, 200-day, and 52-week technical levels?

ALT last traded at $2.14 (+1.91% on volume of 2,684,177 shares), positioning the stock -24.38% below its 50-day simple moving average ($2.83) and -34.76% below its 200-day simple moving average ($3.28). Across its 52-week range of $1.99 to $6.44, ALT sits at the 3.4% percentile with a 14-day RSI of 26.7 (OVERSOLD (<32)) and an implied next-earnings move of ±10.6% ($1.91 to $2.37).

ALT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALT stock right now?

Altimmune Inc. (ALT) currently earns a Roarable Rating of D- (Sell — SELL) with 38/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ALT's 12-month price target and RQD AI Jury consensus?

ALT's 12-month base price target is $1.95 (range $1.52 to $6.76), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALT RQD Cockpit ALT 12M Forecast ALT Earnings & Move ALT Dividends & DRIP ALT Insiders & 13F ALT Whale Options ALT Profit Sankey ALT News & Why